March 16-18, 2015; San Diego, CA
Although the novel oral anticoagulants targeting factor Xa have many advantages over warfarin, one major limitation of their use has been the absence of a specific reversal agent. But at the ACC Scientific Sessions, results from a phase 3 trial were presented showing safety and efficacy of andexanet alfa in reversing the effects of rivaroxaban.
A subanalysis of IMPROVE-IT data showed that that intensive lipid-lowering therapy is important to continue long-term even after patients have had a CV event.
At the ACC 2015 Scientific Sessions, Nicolai Koulmann Tegn, MD, Rikshospitalet Oslo University Hospital, Norway, and colleagues presented the results of the After Eighty Study, a randomized, multicenter trial that assessed adverse cardiovascular outcomes following invasive versus conservative therapy among elderly patients (>80 years) with non-ST-elevation ACS (NSTE-ACS).
At the ACC 2015 Scientific Sessions, a team of Australia-based researchers presented the findings of the LEGACY study (Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-up Study). Their goal was to examine whether weight loss is associated with reduced burden in patients with atrial fibrillation (AF).